PR Newswire PharmaOriginal article
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
Phase 1pidnarulexPositive
AI Analysis
Summary
Senhwa Biosciences completed enrollment in a Phase 1b expansion trial of pidnarulex (CX-5461) for advanced solid tumors with homologous recombination deficiency, with clinical study report expected in Q1 2027.
Clinical Trial Data
Phase
1b
Outcome Details
Phase 1b expansion trial enrollment completed; clinical study report expected in Q1 2027
Importance:5/10
Sentiment:
0.60
Phase 1benrollment completeoncologyPARP inhibitorhomologous recombination deficiency
Related Companies
Read the original article
Published by PR Newswire Pharma on August 25, 2026 6:56 AM